Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats

Imène Boujemla, May Fakhoury, Michel Nassar, Homa Adle-Biassette, Marie Françoise Hurteaud, Evelyne Jacqz-Aigrain, Pierre Gressens, Natacha Teissier

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Congenital cytomegalovirus (CMV) infection is the leading infectious cause of birth defects, mental retardation and non-genetic sensorineural hearing loss. Murine models have been developed in order to understand the pathophysiological mechanisms underlying these lesions. These models are being proposed for the validation of therapeutic protocols for clinical use. The aim of this preclinical study was to assess the pharmacokinetics of the reference antiviral molecule, ganciclovir, in order to optimize these protocols and confirm the diffusion of the molecule to the appropriate target zones. Methods Transplacental and intracochlear diffusion of ganciclovir was evaluated in mice and rats. Pharmacokinetics was assessed in adult mice and pups after 5 consecutive days of intraperitoneal injection of ganciclovir. The occurrence of hematological side effects of ganciclovir was evaluated in the different blood cell lineages. Results In adult rats, the intracochlear diffusion of ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreased significantly in ganciclovir-treated newborn mice. Conclusion Our data provide evidence for the intracochlear diffusion of the molecule, which may be relevant for the treatment of sensorineural hearing loss in congenitally-infected children.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalAntiviral Research
Volume132
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Ganciclovir
Pharmacokinetics
Sensorineural Hearing Loss
Cytomegalovirus Infections
Cell Lineage
Clinical Protocols
Intraperitoneal Injections
Leukocyte Count
Intellectual Disability
Antiviral Agents
Blood Cells
Blood Platelets
Erythrocytes
Mothers
Injections
Therapeutics

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Boujemla, I., Fakhoury, M., Nassar, M., Adle-Biassette, H., Hurteaud, M. F., Jacqz-Aigrain, E., ... Teissier, N. (2016). Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Research, 132, 111-115. https://doi.org/10.1016/j.antiviral.2016.05.019

Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. / Boujemla, Imène; Fakhoury, May; Nassar, Michel; Adle-Biassette, Homa; Hurteaud, Marie Françoise; Jacqz-Aigrain, Evelyne; Gressens, Pierre; Teissier, Natacha.

In: Antiviral Research, Vol. 132, 01.08.2016, p. 111-115.

Research output: Contribution to journalArticle

Boujemla, I, Fakhoury, M, Nassar, M, Adle-Biassette, H, Hurteaud, MF, Jacqz-Aigrain, E, Gressens, P & Teissier, N 2016, 'Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats', Antiviral Research, vol. 132, pp. 111-115. https://doi.org/10.1016/j.antiviral.2016.05.019
Boujemla I, Fakhoury M, Nassar M, Adle-Biassette H, Hurteaud MF, Jacqz-Aigrain E et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Research. 2016 Aug 1;132:111-115. https://doi.org/10.1016/j.antiviral.2016.05.019
Boujemla, Imène ; Fakhoury, May ; Nassar, Michel ; Adle-Biassette, Homa ; Hurteaud, Marie Françoise ; Jacqz-Aigrain, Evelyne ; Gressens, Pierre ; Teissier, Natacha. / Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. In: Antiviral Research. 2016 ; Vol. 132. pp. 111-115.
@article{cf429bee6bf34aa3941f6437a14abf6d,
title = "Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats",
abstract = "Background Congenital cytomegalovirus (CMV) infection is the leading infectious cause of birth defects, mental retardation and non-genetic sensorineural hearing loss. Murine models have been developed in order to understand the pathophysiological mechanisms underlying these lesions. These models are being proposed for the validation of therapeutic protocols for clinical use. The aim of this preclinical study was to assess the pharmacokinetics of the reference antiviral molecule, ganciclovir, in order to optimize these protocols and confirm the diffusion of the molecule to the appropriate target zones. Methods Transplacental and intracochlear diffusion of ganciclovir was evaluated in mice and rats. Pharmacokinetics was assessed in adult mice and pups after 5 consecutive days of intraperitoneal injection of ganciclovir. The occurrence of hematological side effects of ganciclovir was evaluated in the different blood cell lineages. Results In adult rats, the intracochlear diffusion of ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreased significantly in ganciclovir-treated newborn mice. Conclusion Our data provide evidence for the intracochlear diffusion of the molecule, which may be relevant for the treatment of sensorineural hearing loss in congenitally-infected children.",
author = "Im{\`e}ne Boujemla and May Fakhoury and Michel Nassar and Homa Adle-Biassette and Hurteaud, {Marie Fran{\cc}oise} and Evelyne Jacqz-Aigrain and Pierre Gressens and Natacha Teissier",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.antiviral.2016.05.019",
language = "English (US)",
volume = "132",
pages = "111--115",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats

AU - Boujemla, Imène

AU - Fakhoury, May

AU - Nassar, Michel

AU - Adle-Biassette, Homa

AU - Hurteaud, Marie Françoise

AU - Jacqz-Aigrain, Evelyne

AU - Gressens, Pierre

AU - Teissier, Natacha

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background Congenital cytomegalovirus (CMV) infection is the leading infectious cause of birth defects, mental retardation and non-genetic sensorineural hearing loss. Murine models have been developed in order to understand the pathophysiological mechanisms underlying these lesions. These models are being proposed for the validation of therapeutic protocols for clinical use. The aim of this preclinical study was to assess the pharmacokinetics of the reference antiviral molecule, ganciclovir, in order to optimize these protocols and confirm the diffusion of the molecule to the appropriate target zones. Methods Transplacental and intracochlear diffusion of ganciclovir was evaluated in mice and rats. Pharmacokinetics was assessed in adult mice and pups after 5 consecutive days of intraperitoneal injection of ganciclovir. The occurrence of hematological side effects of ganciclovir was evaluated in the different blood cell lineages. Results In adult rats, the intracochlear diffusion of ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreased significantly in ganciclovir-treated newborn mice. Conclusion Our data provide evidence for the intracochlear diffusion of the molecule, which may be relevant for the treatment of sensorineural hearing loss in congenitally-infected children.

AB - Background Congenital cytomegalovirus (CMV) infection is the leading infectious cause of birth defects, mental retardation and non-genetic sensorineural hearing loss. Murine models have been developed in order to understand the pathophysiological mechanisms underlying these lesions. These models are being proposed for the validation of therapeutic protocols for clinical use. The aim of this preclinical study was to assess the pharmacokinetics of the reference antiviral molecule, ganciclovir, in order to optimize these protocols and confirm the diffusion of the molecule to the appropriate target zones. Methods Transplacental and intracochlear diffusion of ganciclovir was evaluated in mice and rats. Pharmacokinetics was assessed in adult mice and pups after 5 consecutive days of intraperitoneal injection of ganciclovir. The occurrence of hematological side effects of ganciclovir was evaluated in the different blood cell lineages. Results In adult rats, the intracochlear diffusion of ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreased significantly in ganciclovir-treated newborn mice. Conclusion Our data provide evidence for the intracochlear diffusion of the molecule, which may be relevant for the treatment of sensorineural hearing loss in congenitally-infected children.

UR - http://www.scopus.com/inward/record.url?scp=84973544401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973544401&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.05.019

DO - 10.1016/j.antiviral.2016.05.019

M3 - Article

C2 - 27260855

AN - SCOPUS:84973544401

VL - 132

SP - 111

EP - 115

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -